בינוקריט 6000 יחבל  0.6 מל ישראל - עברית - Ministry of Health

בינוקריט 6000 יחבל 0.6 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 6000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 10000 יחבל  1 מל ישראל - עברית - Ministry of Health

בינוקריט 10000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 10000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 20000 יחבל  0.5 מל ישראל - עברית - Ministry of Health

בינוקריט 20000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 3000 יחבל  0.3 מל ישראל - עברית - Ministry of Health

בינוקריט 3000 יחבל 0.3 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 3000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 40000 יחבל  1 מל ישראל - עברית - Ministry of Health

בינוקריט 40000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

TraumaCad ישראל - עברית - Ministry of Health

traumacad

voyant health ltd. - רופא - the traumacad program is indicated for assisting healthcare professionals in preoperative planning of orthopedic surgery. the device allows for overlaying of prosthesis templates on radiological images, and includes tools for performing measurements on the image and for positioning the template.

פרוגרם ליפוזום- קרם יום ולילה הנספג בקלות ישראל - עברית - Ministry of Health

פרוגרם ליפוזום- קרם יום ולילה הנספג בקלות

המרכז לקוסמטיקאיות בעמ - צמצום קמטים וקמטוטים

סינרל ישראל - עברית - Ministry of Health

סינרל

pfizer pfe pharmaceuticals israel ltd - nafarelin acetate - תמיסה לאף - nafarelin acetate 2 mg/ml - nafarelin - nafarelin - - controlled ovarian stimulation programmes prior to in-vitro fertilisation.- hormonal management of endometriosis, including pain relief and reduction of endometrial lesions. - uterine fibroids.

פרגניל 5000 יח' בינל ישראל - עברית - Ministry of Health

פרגניל 5000 יח' בינל

merck sharp & dohme israel ltd - human chorionic gonadotropin - אבקה להכנת תמיסה לזריקה - human chorionic gonadotropin 5000 iu/ml - chorionic gonadotrophin - chorionic gonadotrophin - in the female: ovulation induction in infertility due to anovulation or impaired follicle-ripening. preparation of follicles for puncture in controlled ovarian hyperstimulation programs. luteal phase support. in the male: hypogonadotropic hypogonadism (also cases of idiopathic dysspermias have shown a positive response to gonadotropins). delayed puberty associated with insufficient gonadotropic pituitary function.cryptorchidism not due to anatomical obstruction.

פוסטימון 75 IU ישראל - עברית - Ministry of Health

פוסטימון 75 iu

tzamal bio-pharma ltd - urofollitropin - אבקה להכנת תמיסה לזריקה - urofollitropin 75 iu/vial - urofollitropin - urofollitropin - a treatment with fsh followed by the administration of human chronic gonadotrophin (hcg) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. these women belong to the who group ii and have generally already been treated with clomiphene citrate. most have polycystic ovarian syndrome. fsh offers good therapeutic prospects for patients whose lh:fsh ratio has to be adjusted, avoiding an exogenous supply of lh fsh may be used alone or in concomitance with human menopausal gonadotropin (hmg) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (ivf-et,gift).